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The pharmacology of itch 
Pruritus, commonly known as itch, has a substantial impact on quality of life in skin disease. Irritation 
of one of the largest organs of the body does not just directly impact upon the organ itself but 
underlies a plethora of indirect consequences for the patient that goes way beyond the desire to 
scratch. The psychological issues associated with chronic pruritus combine with disfigurement from 
scratching and sleep disturbance to produce mental health problems in many cases. While itch may 
be a consequence of cutaneous inflammation, symptom improvement by modulation of pruritus 
represents an important pharmacological target. There has been a lot of activity in the field recently, 
at both pre-clinical and clinical ends of the spectrum, providing a compelling case for a joint virtual 
issue between the BJP and BJD with a focus on novel therapeutics for pruritus. As the editors of the 
two journals we have each picked seven recent articles to share with our combined audiences. 
Readers of BJP may not be aware that the BJD has a focus on particular core methodologies which 
determine the main sections of the journal: translational, trials, outcomes and qualitative research, 
epidemiology, and evidence-based dermatology. Similarly, BJD readers may not be aware that BJP is 
often the journal of choice for those researchers interrogating the mechanisms of pruritis and the 
testing of novel entities in appropriate in vitro and in vivo experimental models. 
Considering translational research first, our virtual issue contains a review of Substance P and 
neurokinin 1 receptor as targets for the treatment of chronic pruritus.1 Both entities are over-
expressed in multiple chronic pruritic conditions, providing a rationale for translational therapeutic 
applications. The review covers several recent phase 2 clinical trials of neurokinin 1 receptor 
antagonists demonstrating potential clinical benefit. In addition, we include two original articles 
providing greater depth into our understanding of the mechanisms involved in activation of the 
sensory neurones containing these neuropeptides.  We share evidence implicating both TMEM16A 
and reactive nitrogen species in activating TRPV1 and TRPA1 channels localised to nerve endingsa,b, 
thus identifying potential new avenues for limiting the itch sensation.  
BJP has long been a journal home to developments in histamine and histamine receptor 
pharmacology. Accordingly in this issue we share the most recent updates on the role and targeting 
of histamine in itch and associated painc and recent progress in application of molecules targeting 
the H4 receptor particularlyd. The journal is also home to some of the best pharmacology in purified 
natural products, an area with an explosion of interest in the recent decade. This explosion is 
exemplified by a recent article demonstrating the potential of Salvinorin A analogues preventing 
mast cell degranulation, and in this way potentially break the continuous cycle created by physical 
disruption of mast cells of itch-relief-itche.  
 
BJP also has a long history in publishing research emanating from the prostaglandin field, being a 
title that has published some of the most highly cited papers in the field from the Nobel prize 
winning pharmacologist Sir John Vane; the 20 year anniversary of which was recently celebrated in a 
separate themed issue in the journalf. In this Virtual Issue we also include some exciting evidence 
identifying further utility for the somewhat maligned COX-2 inhibitors in modifying TRPV3 activityg.    
Oral Janus kinase (JAK)/spleen tyrosine kinase (SYK) inhibitors are one of the new set of small 
molecules that are under development for dermatological applications, including the pruritus 
associated with atopic dermatitis (AD). In a phase 1B randomised controlled trial investigating 
ASN002, an oral JAK/SYK inhibitor for moderate to severe AD, a 50 percent reduction in Eczema Area 
and Severity Index (EASI 50) was reached by a significantly higher proportion of patients who 
received higher doses of ASN002 compared to placebo.2 
The BJD has established a strong pedigree in publishing outcomes research, which usually requires a 
qualitative aspect in the form of patient interviews to demonstrate content validity. Yosipovitch and 
colleagues combined patient interviews with trial data to establish that peak pruritus numerical 
rating scale is a reliable, sensitive and valid scale for assessing worst itch intensity in adults with 
moderate-to-severe AD.3 
As mentioned in the introductory paragraph, one important potential consequence of chronic 
pruritus is a detrimental effect on mental health. Silverberg and colleagues performed a cross-
sectional, population-based study of 2893 U.S. adults with AD and found significantly increased risks 
of anxiety and depression, using Hospital Anxiety and Depression Scale (HADS) scores, compared to 
those without AD.4 Some of the individuals with elevated HADS scores had not received a formal 
diagnosis, emphasizing the need for vigilance in this patient group. 
The BJD champions evidence-based dermatology. A review article included in this virtual issue 
considers the problem of severe, treatment resistant pruritus associated with primary biliary 
cholangitis (PBC) in which destruction of liver bile ducts leads to intrahepatic cholestasis.5 Our 
understanding of pathophysiology is summarised by the review, including specific receptors such as 
G-protein-coupled bile acid receptor, Gpbar1 (TGR5) and the nuclear transcription factor farnesoid X 
receptor (FXR). Phototherapy can have some benefit and Hussain and co-authors employed a 
focused search strategy to propose testable hypotheses for the mechanism of action of 
phototherapy through modulation of these signalling pathways. 
Explanatory randomised controlled trials generally have tight inclusion and exclusion criteria and 
their results may not always be generalizable to the wider patient population. So it is important to 
have real-world data to fill the gap. A study of 95 adult patients who received dupilumab for AD in 
the Netherlands in a non-trial setting found that results were in keeping with the phase III trial data 
for clinically relevant improvement of both physician-reported and patient-reported severity scores.6 
As part of the BJD portion of this issue the BJD editor has included one additional ‘editor’s choice’ 
article. As dermatologists we may take for granted use of newer antihistamines that have a lower 
tendency to cause drowsiness than first generation antihistamines (FGA). A cross-sectional 
observational study from the U.S. investigated antihistamine prescriptions following 15,000 
dermatology consultations and 66,000 primary care appointments.7 The study found that FGA 
prescribing rates were 2-fold higher in primary care than secondary care when comparing matched 
cohorts. In addition, there was no reduction in prescribing rates in older adults, despite FGA being 
classified as “potentially inappropriate” in this population.   
In sum, there has been considerable interest in the field of pruritis, not only in terms of direct 
treatment to attenuate the sensation and its physical consequences but also in terms of dealing with 
the sometime devastating effects upon mental health.  This virtual issue bringing the BJP and BJD 
together shines a spotlight upon the most recent advances in the field in both journals.  
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